ArticleOncoimmunology2015
Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.Journal for immunotherapy of cancer · 2024Trial
- Peripheral Blood TCR Clonotype Diversity as a Biomarker for Colorectal Cancer.Bioengineering (Basel, Switzerland) · 2025Article
- Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity.Immunologic research · 2024Article
- A clinical-information-free method for early diagnosis of lung cancer from the patients with pulmonary nodules based on backpropagation neural network model.Computational and structural biotechnology journal · 2024Article
- Human TCR repertoire in cancer.Cancer medicine · 2024Review
- Identification and tracking of HTLV-1-infected T cell clones in virus-associated neurologic disease.JCI insight · 2023Article
- RNA-Seq and Immune Repertoire Analysis of Normal and Hepatocellular Carcinoma Relapse After Liver Transplantation.International journal of general medicine · 2023Article
- T-cell repertoire diversity: friend or foe for protective antitumor response?Journal of experimental & clinical cancer research : CR · 2022Review
- Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma.Frontiers in immunology · 2022Article
- Human immune repertoire in hepatitis B virus infection.World journal of gastroenterology · 2021Review
- Blood T cell diversity associated with the prognosis of advanced non-small cell lung carcinoma treated with first-line pemetrexed based chemotherapy.Thoracic cancer · 2021Article
- Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups.iScience · 2021Article
- Increased lactate in AML blasts upregulates TOX expression, leading to exhaustion of CD8American journal of cancer research · 2021Article
- Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy.Frontiers in oncology · 2021Review
- Longitudinal High-Throughput Sequencing of the T-Cell Receptor Repertoire Reveals Dynamic Change and Prognostic Significance of Peripheral Blood TCR Diversity in Metastatic Colorectal Cancer During Chemotherapy.Frontiers in immunology · 2021Article
- Decreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves' Disease.Frontiers in endocrinology · 2021Article
- Clonal expansion of bone marrow CD8American journal of cancer research · 2020Article
- Characterization of Distinct T Cell Receptor Repertoires in Tumor and Distant Non-tumor Tissues from Lung Cancer Patients.Genomics, proteomics & bioinformatics · 2019Article
- Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis.The Journal of clinical investigation · 2019Article
- Determination of the complexity and diversity of the TCR β-chain CDR3 repertoire in bladder cancer using high-throughput sequencing.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer is one of the most common cancers worldwide. CDR3 sequencing-based immune repertoire can be closely associated with cancer prognosis and development. Identifying the specific interaction between the TCR and cellular antigens is important for developing novel immunotherapeutic approaches for the treatment of cancer. The rearranged TCRβ loci amplified using Vβ- and Jβ-specific primers by multi-PCR and sequenced using high-throughput sequencing (HTS) in liver cancers were compared with those of T cells from healthy adult peripheral blood and from adjacent liver tissue. The T-cell repertoires within each tumor show strong similarity to one another but are distinct from those of the circulating T-cell repertoire. In addition, our results demonstrate that there are significant differences in the T-cell repertoires of HCC (hepatocellular carcinoma), ICC (intrahepatic cholangiocarcinoma), and MHC (mixed hepatocellular and cholangiocellular carcinoma). Furthermore, we found that the highly expanded clone (HEC) ratio in blood samples from liver cancer patients differed significantly from those in the blood of healthy adults and hepatitis patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.